000289470 001__ 289470
000289470 005__ 20241106102215.0
000289470 0247_ $$2doi$$a10.3390/cancers16071276
000289470 0247_ $$2pmid$$apmid:38610954
000289470 0247_ $$2pmc$$apmc:PMC11010873
000289470 0247_ $$2altmetric$$aaltmetric:162413876
000289470 037__ $$aDKFZ-2024-00792
000289470 041__ $$aEnglish
000289470 082__ $$a610
000289470 1001_ $$00000-0002-9659-2703$$aSalvato, Ilaria$$b0
000289470 245__ $$aImmunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.
000289470 260__ $$aBasel$$bMDPI$$c2024
000289470 3367_ $$2DRIVER$$aarticle
000289470 3367_ $$2DataCite$$aOutput Types/Journal article
000289470 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1713268812_20784$$xReview Article
000289470 3367_ $$2BibTeX$$aARTICLE
000289470 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289470 3367_ $$00$$2EndNote$$aJournal Article
000289470 500__ $$a#LA:D490#
000289470 520__ $$aDespite decades of research and the best up-to-date treatments, grade 4 Glioblastoma (GBM) remains uniformly fatal with a patient median overall survival of less than 2 years. Recent advances in immunotherapy have reignited interest in utilizing immunological approaches to fight cancer. However, current immunotherapies have so far not met the anticipated expectations, achieving modest results in their journey from bench to bedside for the treatment of GBM. Understanding the intrinsic features of GBM is of crucial importance for the development of effective antitumoral strategies to improve patient life expectancy and conditions. In this review, we provide a comprehensive overview of the distinctive characteristics of GBM that significantly influence current conventional therapies and immune-based approaches. Moreover, we present an overview of the immunotherapeutic strategies currently undergoing clinical evaluation for GBM treatment, with a specific emphasis on those advancing to phase 3 clinical studies. These encompass immune checkpoint inhibitors, adoptive T cell therapies, vaccination strategies (i.e., RNA-, DNA-, and peptide-based vaccines), and virus-based approaches. Finally, we explore novel innovative strategies and future prospects in the field of immunotherapy for GBM.
000289470 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000289470 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289470 650_7 $$2Other$$aCAR-T cell therapy
000289470 650_7 $$2Other$$aDNA/RNA vaccines
000289470 650_7 $$2Other$$aGBM
000289470 650_7 $$2Other$$aGBM immunosuppressive tumor microenvironment
000289470 650_7 $$2Other$$aadoptive cell therapy
000289470 650_7 $$2Other$$aimmune checkpoint therapy
000289470 650_7 $$2Other$$aimmunotherapy
000289470 650_7 $$2Other$$aoncolytic virotherapy
000289470 650_7 $$2Other$$avaccination therapy
000289470 7001_ $$0P:(DE-He78)2c1968abb9781c0328997892355fa74c$$aMarchini, Antonio$$b1$$eLast author$$udkfz
000289470 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers16071276$$gVol. 16, no. 7, p. 1276 -$$n7$$p1276$$tCancers$$v16$$x2072-6694$$y2024
000289470 8564_ $$uhttps://inrepo02.dkfz.de/record/289470/files/cancers-16-01276-v3.pdf
000289470 8564_ $$uhttps://inrepo02.dkfz.de/record/289470/files/cancers-16-01276-v3.pdf?subformat=pdfa$$xpdfa
000289470 909CO $$ooai:inrepo02.dkfz.de:289470$$pVDB
000289470 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2c1968abb9781c0328997892355fa74c$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000289470 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000289470 9141_ $$y2024
000289470 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000289470 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000289470 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000289470 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-31T16:07:06Z
000289470 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000289470 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000289470 9202_ $$0I:(DE-He78)D490-20160331$$kD490$$lKKE Virotherapie$$x0
000289470 9201_ $$0I:(DE-He78)F230-20160331$$kF230$$lKKE Virotherapie$$x0
000289470 9201_ $$0I:(DE-He78)D490-20160331$$kD490$$lKKE Virotherapie$$x1
000289470 980__ $$ajournal
000289470 980__ $$aVDB
000289470 980__ $$aI:(DE-He78)F230-20160331
000289470 980__ $$aI:(DE-He78)D490-20160331
000289470 980__ $$aUNRESTRICTED